MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

20th International Congress » Other

Date: Thursday, June 23, 2016

Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Session Type: Poster Session

Meeting: 20th International Congress

12:00pm-1:30pm
“Words untold”

P.M. Iyer, B. McGuiness, J. Scott, S. Manning, A. Chalisseri, D. Olszewska, M. Farrell, T. Lynch (Dublin, Ireland)

12:00pm-1:30pm
A case of hemifacial spasm with a right-sided pontine meningioma that resolved with PICA loop vascular decompression surgery

E.M. Feinstein, S.J. Frucht (New York, NY, USA)

12:00pm-1:30pm
A case with posttraumatic functional shoulder dyskinesia

S. Tezcan, M. Demirci, M.C. Akbostanci (Ankara, Turkey)

12:00pm-1:30pm
A community organizing approach to identify and address the barriers to healthcare for XDP patients in Panay Island, Philippines

G.M. Solinap, A.C. Aguil, P.B. Acuna, L.V. Lee, N. Sharma (Charlestown, MA, USA)

12:00pm-1:30pm
A comparison of standards of care in Parkinson’s disease between a general neurology clinic and a specialist movement disorders clinic based on the UK NICE guidelines

S.M. Yap, M.O. Dablouk, S. O'Sullivan (Dublin, Ireland)

12:00pm-1:30pm
A cross-linguistic approach to speech intelligibility in people with PD

Y. Kim, Y. Choi (Baton Rouge, LA, USA)

12:00pm-1:30pm
A heterozygous splicing mutation c.823-10G>T at the intron9/exon 10 of the MAPT gene in an Irish family with FTDP- 17

E.M. Fallon, D.A. Olszewska, C. McGuigan, I. Delon, F. Brett, B. Lawlor, M. Hutchinson, M. Hutton, T. Lynch (Dublin, Ireland)

12:00pm-1:30pm
A new test for the measuring hand functions in Parkinson’s disease: Psychometric evaluation of the squares test

E. Goz, F. Soke, A. Genc, B. Donmez Colakoglu, P. Keskinoglu (Izmir, Turkey)

12:00pm-1:30pm
A rapid chemical-genetic screen utilising impaired movement phenotypes in caenorhabditis elegans

K. Schmeisser, Y.F. Ghassemi, C. Maios, A. Parker (Montreal, QC, Canada)

12:00pm-1:30pm
Adult onset Niemann-Pick type C: 24 month follow-up on miglustat

B. Elibol, F. Ozkinay, H. Onder (Ankara, Turkey)

12:00pm-1:30pm
Aquatic physical therapy: Functional motor skills in people with Parkinson’s disease

V.L. Israel, B. Yamaguchi, V.L. Israel (Curitiba, Brazil)

12:00pm-1:30pm
Assessment of oral hygiene status before and after the use of powered tooth brush in patients with Parkinson’s diseases

F. Pullishery, F.M. Kuyyadi (Malappuram, India)

12:00pm-1:30pm
Association of amyotrophic lateral sclerosis with basal ganglia impairment

D. Mirzaeva, A. Prokhorova, B. Muinjanov, P. Deleyn (Tashkent, Uzbekistan)

12:00pm-1:30pm
Beliefs and knowledge on Parkinson’s disease (PD) among people with PD, the public and traditional healers in Western Cape, South Africa

J. Mokaya, J. Carr (Tygerberg, South Africa)

12:00pm-1:30pm
Beyond 30 years of Parkinson’s disease: A comprehensive characterization of long-surviving patients

A. Romagnolo, M.G. Rizzone, F. Dematteis, M. Zibetti, A. Merola, L. Rizzi, E. Montanaro, C.A. Artusi, M. Lanotte, L. Lopiano (Turin, Italy)

12:00pm-1:30pm
Biochemical features of lipids spectrum in blood in patients with Parkinson’s disease

Z.A. Akbarkhodjaeva, F. Saidvaliev (Tashkent, Uzbekistan)

12:00pm-1:30pm
Characterization of European longitudinal cohort studies in Parkinson’s disease – Report of the JPND working group BioLoC-PD

S. Lerche, I. Liepelt-Scarfone, G. Alves, P. Barone, S. Behnke, Y. Ben-Shlomo, H. Berendse, D. Burn, R. Dodel, D. Grosset, M. Hu, M. Kasten, R. Krüger, W. Maetzler, B. Mollenhauer, W. Oertel, U. Walter, K. Wirdefeldt, D. Berg (Tübingen, Germany)

12:00pm-1:30pm
Colonic α-synuclein: A potential diagnostic biomarker in Parkinson’s disease

C. Ruffmann, I. Poggiolini, N. Bengoa-Vergniory, F. Baig, M. Rolinski, J. Klein, M.T. Hu, R. Wade-Martins, J. Alegre-Abarrategui, L. Parkkinen (Oxford, United Kingdom)

12:00pm-1:30pm
Comparing quality of PD care in a comprehensive clinic to specialist care

S.A. Factor, L.P. Prizer, F.C. Goldstein, L.M. Trotti, A. Hermida, C. Vaughan (Atlanta, GA, USA)

12:00pm-1:30pm
Conjugal Parkinson´s disease – Real or chance?

B. Balint, R. Erro, F. Brugger, A. Batla, E. Antelmi, C. Ganos, K.P. Bhatia (London, United Kingdom)

12:00pm-1:30pm
Coupling between visual information and body sway in people with Parkinson’s disease

C.F. Cruz, L.A.O.A. Nóbrega, E. Okamoto, M.E.P. Piemonte, J.A. Barela (São Paulo, Brazil)

12:00pm-1:30pm
Creutzfeldt-Jakob disease presenting predominantly with movement disorder: A case report

A.A. Sann, M.M. Zaw, T.L. Choie (Yangon, Myanmar)

12:00pm-1:30pm
CSF level of chromogranin A in amyotrophic lateral sclerosis

M. Kaiserova, P. Otruba, K. Mensikova, Z. Grambalova, H. Prikrylova Vranova, J. Mares, D. Stejskal, P. Kanovsky (Olomouc, Czech Republic)

12:00pm-1:30pm
Deep brain stimulation of the locomotor mesencephalic region in rats with lesioned sensorimotor cortex: A model of functional motor recovery after stroke

F. Fluri, M.K. Schuhmann, C. Kleinschnitz, J. Volkmann (Würzburg, Germany)

12:00pm-1:30pm
Development of a nanoherbaceutical containing natural L-DOPA from mucuna pruriens for the prevention and treatment of Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced animal model

P.C. Bhatt, V. Kumar (New Delhi, India)

12:00pm-1:30pm
Differences in physicians’ understanding of biologic and biosimilar medicines in the USA and Europe

A.L. Molinari, H.L. Gewanter, M. Reilly, D. Charles (Washington, DC, USA)

12:00pm-1:30pm
Duration of levodopa treatment and prevalence of osteoporosis in patients with Parkinson’s disease

S.H. Guptha (Peterborough, United Kingdom)

12:00pm-1:30pm
ECG-based cardiopulmonary coupling for sleep stability assessment in patients with amyotrophic lateral sclerosis

S. Mariani, P. Congiu, G. Milioli, G. Gioi, G. Borghero, F. Marrosu, R.J. Thomas, A.L. Goldberger, M. Puligheddu (Boston, MA, USA)

12:00pm-1:30pm
EEG Spectral power changes prior to non-epileptic seizures: A pilot study

A.M. Meppelink, I. Parees, M. Beudel, S. Little, M. Edwards (Groningen, Netherlands)

12:00pm-1:30pm
Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism

M.U. Kulmanova (Tashkent, Uzbekistan)

12:00pm-1:30pm
Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia

W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, M. Sanchez, W. Shanahan (New York, NY, USA)

12:00pm-1:30pm
Effectiveness of Lee Silverman voice treatment big on improving gait and quality of life in Parkinson’s disease patients after STN-DBS

V.V.P. Kagita, N.N. Mohd, A.K. Puligopu, R.M. Kandadai, M.A. Kanikannan, S. Jabeen, R. Borgohain (Hyderabad, India)

12:00pm-1:30pm
Effects of movement rate and amplitude on repetitive finger motion in people with Parkinson’s disease and freezing of gait

M.P. Pereira, S. Vercruysse, E. Heremans, A. Nieuwboer (Leuven, Belgium)

12:00pm-1:30pm
European physiotherapy guideline for Parkinson’s disease: Information for neurologists

D.L.M. Radder, M.J. Faber, N.M. de Vries, B.R. Bloem, S.H.J. Keus (Nijmegen, Netherlands)

12:00pm-1:30pm
Evaluation of respiratory and depression levels of patients with Parkinson’s disease

E.E. Okuyucu, O. Canbay, E. Dogru, I. Huzmeli, N. Katayifci, F. Duman, N.C. Korkmaz, B. Yucekaya, E. Seker (Hatay, Turkey)

12:00pm-1:30pm
Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia

W. Wen, K. Kishnani, S. Ramaswamy, S. Piscitelli (New York, NY, USA)

12:00pm-1:30pm
Exploring hospitalizations and visits to the emergency room of patients with Parkinson’s disease: A ten years’ follow-up

M.T. Montojo, Y. Macias, M. ÁLvarez, C. Martín, L. Borrega, L. Vela (Alcorcón, Spain)

12:00pm-1:30pm
Factors affecting the cardiac sympathetic denervation in autopsy confirmed dementia with Lewy bodies

M. Takahashi, T. Uchihara, M. Yoshida, K. Wakabayashi, A. Kakita, H. Takahashi, S. Toru, T. Kobayashi, S. Orimo (Tokyo, Japan)

12:00pm-1:30pm
Fall status and stepping response: Individuals with PD are differently influenced by side-affected

B.N. Intzandt, E. Beck, M.P. Pereira, Q.J. Almeida (Waterloo, ON, Canada)

12:00pm-1:30pm
Finding an optimal lead trajectory for a better stimulated volume in movement disorder therapy

J. Perez, L. Cif, V. Gonzalez, E. Sanrey, F. Cyprien, P. Coubes (Montpellier, France)

12:00pm-1:30pm
Frequency of falls in nursing homes for neurodegenerative diseases

C. Godinho, J.M. Domingos, A.S. Pereira, M. Duarte, J.J. Ferreira (Lisboa, Portugal)

12:00pm-1:30pm
Gait and anthropometric characteristics of patients with Parkinson’s disease seen in a Nigerian tertiary hospital

A.O. Ogundele, M.O. Olaogun, M.A. Komolafe (Ile-Ife, Nigeria)

12:00pm-1:30pm
Gender-dependent behavioral and biochemical differences in the A53T genetic mouse model of Parkinson’s disease

G. Costa, M.J. Sisalli, L. Contu, A. Scorziello, M. Morelli (Cagliari, Italy)

12:00pm-1:30pm
Glial cells and iron accumulation in the brain of the Zitter rat

T. Kadowaki, H. Lassmann, S. Ueda, C. Schuh, K. Hirata (Mibu, Japan)

12:00pm-1:30pm
Has iCare PD started in Singapore?

S.H.X. Liew, C. Cyq, N. Jcf, K. Sym, R.C.L. Ong (Singapore, Singapore)

12:00pm-1:30pm
Home care program for patients with Parkinson’s disease – A Singapore experience

H.L. Ng, W. Li, S. Abdul Karim, K.Y. Tay, W.L. Au, L.C.S. Tan (Singapore, Singapore)

12:00pm-1:30pm
How accurate is the prediction of driving ability in a Parkinson’s clinic setting?

C. Thomas, R. Amin, B. Mohamed (Cardiff, United Kingdom)

12:00pm-1:30pm
Improving the experience of diagnosis in Parkinson’s disease

C. Carroll, B. Blight, V. Evans, N. Hawkes, J. Davis (Plymouth, United Kingdom)

12:00pm-1:30pm
Incidence of fragility fractures in people with parkinsonism [PwP] – A 5 year retrospective observational study

S. Aithal, C. Thomas, S. Raha, H. Shukla, L. Ebenezer, R. Sequeria, B. Mohamed (Caerphilly, United Kingdom)

12:00pm-1:30pm
Interdisciplinary allied health care in a southern Brazil service

V.L. Israel, B. Yamaguchi, V.L. Israel (Curitiba, Brazil)

12:00pm-1:30pm
Is physiotherapy an effective for treatment of Parkinson’s disease?!

R. Agzamov, S. Tursunov, G. Rakhimbaeva, F. Yunusov, D. Lutfullaeva, J. Olimov, A. Kalendarev, K. Abdukhalimova, R. Mirzaev (Tashkent, Uzbekistan)

12:00pm-1:30pm
Long-latency somatosensory evoked potentials of the subthalamic nucleus

C. Trenado, S. Elben, L. Friggemann, S. Gruhn, S. Groiss, J. Vesper, A. Schnitzler, L. Wojtecki (Düsseldorf, Germany)

12:00pm-1:30pm
Loss of heart rate variability in ALS: Time and frequency domain assessment

P. Congiu, G. Milioli, G. Borghero, G. Gioi, F. Marrosu, M. Puligheddu, A.L. Goldberger, S. Mariani (Monserratoo, Italy)

12:00pm-1:30pm
Nursing diagnoses and interventions in rehabilitation related to antiParkinsonian pharmacotherapy

M.H.S. Tosin, B.G.R.B. Oliveira, T.R. Garcia (Rio de Janeiro, Brazil)

12:00pm-1:30pm
Ocular flutter in alcohol withdrawal syndrome

K.P. Frei, M. Dastjerdi, F.B. Pedouim, L.H. Sovory, K. Dashtipour (Loma Linda, CA, USA)

12:00pm-1:30pm
Osmotic demyelination syndrome with dystonia and parkinsonism responsive to dopaminergic therapy

L.E. Katus, S.J. Frucht (New York, NY, USA)

12:00pm-1:30pm
Parkinson’s disease (PD) quality improvement measures (QIM) and outcomes study

J. Martello, L. Shulman, M. Armstrong, S. Reich (Baltimore, MD, USA)

12:00pm-1:30pm
Parkinsonism due to hypermanganism in the background of cirrhosis and recovery by CaNaEDTA

B. Elibol, H. Onder, G.Y. Cakmakli, E.S. Topcuoglu (Ankara, Turkey)

12:00pm-1:30pm
Participant feedback in the PREDICT-PD study

C.W. Osborne, J. Bestwick, G. Giovannoni, A.J. Lees, A. Schrag, A. Noyce (London, United Kingdom)

12:00pm-1:30pm
Physical therapy, a third wheel in the management of Parkinson’s disease

M.V. Alvarez, M. Rodriguez (San Antonio, TX, USA)

12:00pm-1:30pm
Physiological and biomechanical responses of people with Parkinson’s during Zumba Gold®: Effects of dance styles and number of sessions

A. Delextrat, J. Bateman, P. Esser, N. Targen, H. Dawes, M.A. Delextrat (Oxford, United Kingdom)

12:00pm-1:30pm
Physiotherapy can reduce the decline in functioning according to ICF framework in patients in early stage of Parkinson’s disease evolution

E.T.N. Guelfi, E. Okamoto, F.B. Tarallo, J.C. Elmauer, R.R. Fermino, V.F. Giangiardi, P. Yuki, E.P. Piemonte (São Paulo, Brazil)

12:00pm-1:30pm
Predicting risk of sarcopenia in people with Parkinson’s disease

A.P.C. Loureiro, B. Yamaguchi, I.L.P. Villegas, M.P. Ferreira, V.L. Israel (Curitiba, Brazil)

12:00pm-1:30pm
Predictive validity of statistical models of Parkinson’s disease progression

A. Mendes, A. Gonçalves, N. Vila-Chã, M. Calejo, I. Moreira, J. Fernandes, J. Damásio, A. Bastos-Lima, S. Cavaco (Porto, Portugal)

12:00pm-1:30pm
Prevalence of orthostatic hypotension after a low subacute levodopa dose in patients with parkinsonism

G. Calandra-Buonaura, L. Sambati, I. Gessaroli, A. Turrini, R. Terlizzi, G. Giannini, P. Guaraldi, P. Cortelli (Bologna, Italy)

12:00pm-1:30pm
Profile of urgent care visits in movement disorders

J.T. Lazarus, V.D. Sharma, L. Scorr, S. Factor (Atlanta, GA, USA)

12:00pm-1:30pm
Progressive encephalomyelitis with rigidity and myoclonus (PERM) in an intellectually disabled patient initially misdiagnosed as neuroleptic malignant syndrome (NMS)

Z. Xu, K. Prasad, T. Yeo (Singapore, Singapore)

12:00pm-1:30pm
Psychogenic non-epileptic seizures among patients with temporal lobe and other epilepsies: Phenomenology and EEG correlates

B.D. Wissel, A.K. Dwivedi, T.E. Gaston, F.J. Rodriguez-Porcel, D. Al Jaafari, J.L. Hopp, A. Krumholz, Y. Wang, S.M.A. van der Salm, D.M. Andrade, F. Borlot, B.D. Moseley, J.L. Cavitt, S. Williams, J. Stone, W.C. LaFrance Jr, J.P. Szaflarski, A.J. Espay (Cincinnati, OH, USA)

12:00pm-1:30pm
Relationship between balance, trunk impairment and hand function in Parkinson’s disease

B. Donmez Colakoglu, F. Soke, A. Genc, P. Keskinoglu (Izmir, Turkey)

12:00pm-1:30pm
Relationship of muscular strength with cardiovascular function in Parkinson’s disease

M.A. Alomari, H. Khalil, O.F. Khabour, E. Dersieh, J.A. Bajwa (Irbid, Jordan)

12:00pm-1:30pm
Reliability of the sensory organization test to predict falls in individuals with Parkinson’s disease

T.E. Apoznanski, S. Yao, M.K. Jung, J. DiFrancisco-Donoghue (Old Westbury, NY, USA)

12:00pm-1:30pm
Risk factors associated with postural changes in Parkinson’s disease

A. Khlebtovsky, O. Keret, Y. Rodity, G. Tsvetov, I. Slutzcki-Shraga, F. Benninger, R. Djaldetti (Petach Tikva, Israel)

12:00pm-1:30pm
Role of the nurse coordinator within a unit for treatment of neuro-surgical behaviours and abnormal movements

E. Borgeais, C. Fournera, I. Creff, P. Coubes (Montpellier, France)

12:00pm-1:30pm
Safety of nelotanserin in a randomized placebo-controlled phase 2 study

W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, S. Piscitelli, M. Sanchez, W. Shanahan (New York, NY, USA)

12:00pm-1:30pm
Sarcopenia and dynapenia in patients with parkinsonism

E. Cassani, E. Cereda, G. Pinelli, L. Iorio, A. Valentino, C. Pusani, V. Ferri, C. Bolliri, M. Pasqua, G. Frazzitta, M. Barichella, G. Pezzoli (Milano, Italy)

12:00pm-1:30pm
Self-perception of vocal handicap in Parkinson’s disease

A.K. Silbergleit, J. Wall, L. Schultz, J. Peacock, P.A. LeWitt (West Bloomfield, MI, USA)

12:00pm-1:30pm
Stiff person syndrome

P. Dosekova, G. Krastev, J. Haring, R. Lackovic (Trnava, Slovakia (Slovak Republic))

12:00pm-1:30pm
Stiff person syndrome: Case series

E. Sasse, G. Amorelli, M. Spitz, C.S.B. Germano, L.F. Vasconcellos (Rio De Janeiro, Brazil)

12:00pm-1:30pm
STRONG VOICE: Design of a multisite, open-label, longitudinal registry for patients with neurogenic dysphonia/dysphagia treated with vocal fold augmentation

K.D. Sethi, A. Verma, C.A. Rosen, C.H. Adler, C.J. Bassich, T.L. Carroll, M.D. Stacy (Raleigh, NC, USA)

12:00pm-1:30pm
Successful treatment of movement disorders after resection of midbrain cavernous malformations: Report of two cases

A. Smolanka, V. Smolanka, K. Karpinska, M. Dovhanych, T. Havryliv (Uzhhorod, Ukraine)

12:00pm-1:30pm
Systems biological approach to Parkinson’s disease- Uncovering effects of PD on the synapse

K.F. Heil, O. Sorokina, J.D. Armstrong, J. Hellgren Kotaleski (Edinburgh, United Kingdom)

12:00pm-1:30pm
Testing for the “whack-a-mole” sign in the movement disorders clinic

J.E. Park, C. Maurer, M. Villegas, M. Hallett (Bethesda, MD, USA)

12:00pm-1:30pm
The communicative effectiveness survey-revised (CESR): An objective measure of communicative participation for people with Parkinson’s disease

N.J. Donovan (Baton Rouge, LA, USA)

12:00pm-1:30pm
The differentiated treatment of Parkinson’s disease in patients with concomitant diabetes mellitus(DM) type 2

F.S. Akhmedova, M.K.U. Tukhtamishev (Tashkent, Uzbekistan)

12:00pm-1:30pm
The effect of daytime working for development of sleep apnea in office workers

D.M. Sultonov, U.N. Vokhidov (Tashkent, Uzbekistan)

12:00pm-1:30pm
The effect of improved nutritional status on psychiatric features and quality of life in Parkinson’s disease patients

N. Ongun, C. Erdogan, E. Degirmenci, L.S. Bir (Denizli, Turkey)

12:00pm-1:30pm
The role of acoustic salience in acoustic cueing and sound-based motor rehabilitation

B.G. Schultz, S.A. Kotz (Maastricht, Netherlands)

12:00pm-1:30pm
The role of active rehabilitation measures, for maintaining the quality of life of patients after stroke with movement disorders in the general practice conditions

G. Sadullaeva (Tashkent, Uzbekistan)

12:00pm-1:30pm
The role of proprioceptive deficits as a mechanism of gait impairments in postural instability and gait disorder Parkinson’s disease subtype

M.P. Pereira, P.H.S. Pelicioni, Q.J. Almeida, L.T.B. Gobbi (Leuven, Belgium)

12:00pm-1:30pm
The serum response factor SRF protect dopamine (DA) neurons in Parkinson’s disease partially by mediate autophagy through a beclin 1-dependent pathway

X. Cheng (Suzhou, People's Republic of China)

12:00pm-1:30pm
Therapeutic effect of onabotulinumtoxinA (BoNT/A) in hemifacial spasm and trigeminal neuralgia post Ramsay Hunt Syndrome type II

R. López-Castellanos, R. López-Contreras (San Salvador, El Salvador)

12:00pm-1:30pm
TNF compromises lysosome acidification and reduces α-synuclein degradation via autophagy in dopaminergic cells

X. Cheng, M. Wang (Suzhou, People's Republic of China)

« View all sessions from the 20th International Congress.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley